Standard treatment regime required for blebitis

Article

A standard treatment regime is required for the management of blebitis.

A standard treatment regime is required for the management of blebitis, revealed a study featured in the British Journal of Ophthalmology.

The anonymous survey was conducted by Dr Patrick Chiam et al., Ophthalmology Department, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, UK, and included 13 questions determining blebitis management. The χ2 analysed any correlations that occurred amongst the participants' answers to the questionnaire.

Data from 68 of the 112 questionnaires, answered by glaucoma consultants, was used in the investigation. It was recorded that 55% of consultants admitted blebitis patients to hospital. A conjuncitval swab was administered to 74% of the patients and 28% were treated with instil iodine on the conjunctiva.

A further 34% of consultants used topical fluroquinolone monotherapy, 28% used cefuroxime and gentamicin, 18% administered fluroquinolone with cefuroxime and 9% used ceftazidime and vancomycin.

Oral antibiotics are prescribed by 69% of consultants and the only antibiotic used is fluroquinolones. Topical corticosteroids are used by 82% of conulstants and 91% use a topical cycloplegic.

Of the consultants who completed the survey, 23% treat blebitis as endophthalmitis, with or without anterior chamber (AC) activity. A further 38% would treat blebitis as endophthalmitis if AC activity was moderate and 34% would if AC activity was severe.

The investigation suggests that, due to the existence of a wide variation in blebitis management regimes, a standard treatment regime is needed.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.